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The broad expression of the insulin receptor
suggests that the spectrum of insulin function has
not been fully described. A cell type expressing
this receptor is the osteoblast, a bone-specific cell
favoring glucose metabolism through a hormone,
osteocalcin, that becomes active once uncarboxy-
lated. We show here that insulin signaling in
osteoblasts is necessary for whole-body glucose
homeostasis because it increases osteocalcin
activity. To achieve this function insulin signaling in
osteoblasts takes advantage of the regulation of
osteoclastic bone resorption exerted by osteoblasts.
Indeed, since bone resorption occurs at a pH acidic
enough to decarboxylate proteins, osteoclasts
determine the carboxylation status and function of
osteocalcin. Accordingly, increasing or decreasing
insulin signaling in osteoblasts promotes or hampers
glucose metabolism in a bone resorption-dependent
manner in mice and humans. Hence, in a feed-
forward loop, insulin signals in osteoblasts activate
a hormone, osteocalcin, that promotes glucose
metabolism.
INTRODUCTION
Bone is a multitasking tissue with mechanical, hematopoietic,
and metabolic functions that result from the tight interplay
between two bone-specific cell types, the osteoblast and the
osteoclast. Bone also emerged recently as an endocrine organ
regulating glucose metabolism (Fukumoto and Martin, 2009),
a function that has been ascribed to date only to the osteoblast.
The intricacy existing between osteoblasts and osteoclasts rai-
ses the prospect, however, that the osteoclast may contribute
to the endocrine role of the skeleton.296 Cell 142, 296–308, July 23, 2010 ª2010 Elsevier Inc.Bone uses the osteoblast-specific secreted molecule osteo-
calcin to favor glucose homeostasis. Circulating osteocalcin
exists in two forms, carboxylated on 3 glutamate residues or
undercarboxylated; the latter form being able to enhance insulin
secretion by b-cells, insulin sensitivity and energy expenditure
(Lee et al., 2007). Osteocalcin (Ocn), however, is not the only
gene expressed in osteoblasts affecting glucose homeostasis.
Esp, a geneencodingan intracellular tyrosinephosphatasecalled
OST-PTP exerts, through its osteoblast expression, metabolic
functions opposite to those of osteocalcin (Lee et al., 2007).
Genetic and biochemical evidence show that Esp acts upstream
of Ocn to inhibit its metabolic function. For instance, the meta-
bolic phenotype of Esp/ mice is fully corrected by removing
one allele of Ocn even though Ocn+/ mice have no metabolic
phenotype, and the fraction of undercarboxylated osteocalcin is
significantly higher inEsp/ than inwild-type (WT)mouse serum.
The role of the osteoblast in regulating glucose metabolism
revealed by these and other findings (Rached et al., 2010a;
Yoshizawa et al., 2009) raises questions. The first one is to
explain how OST-PTP, an intracellular tyrosine phosphatase,
can influence the carboxylation and function of a secreted mole-
cule like osteocalcin. A second issue is to provide evidence that
the same bone-dependent regulation of glucose metabolism
exists in humans since ESP is a pseudogene in this species
(Cousin et al., 2004). A third question of physiological nature
looming beyond these observations is whether insulin, in a feed-
back loop, influences osteocalcin synthesis and/or activity.
The insulin receptor is a tyrosine kinasewhose activity must be
tightly regulated since it can be activated in the absence of ligand
(Kasuga et al., 1983). Receptor tyrosine kinases are often in-
hibited by protein tyrosine phosphatases (PTPs) (Schlessinger,
2000) and PTP1B, which dephosphorylates the insulin receptor,
is a major regulator of insulin signaling in hepatocytes and myo-
cytes (Delibegovic et al., 2007, 2009). The fact that OST-PTP is
a tyrosine phosphatase raises the testable hypothesis that the
insulin receptor is one of its substrates.
Our understanding of insulin signaling in various tissues has
been profoundly altered by the analysis of mutant mouse strains
AFE HG
B
50
50
37
25
kDa GS
T
GS
T-
PT
P1
B 
W
T
GS
T-
PT
P1
B 
DA
In
pu
t (
5%
)
In
pu
t (
2%
)
100
75
kDa
100
75
100
75
100
75
100
75
kDa
100
100
100
75
100
75
100
75
75
75
kDa
100
75
100
75
100
75
kDa
Coomassie 
staining
Coomassie 
staining
ROS17/2.8
IB: InsR IB: InsR
OSB
IB: InsR
IB: P-InsR
(Y1150/Y1151)
IB: P-InsR
(Y1150/Y1151)
pFLAG
OST-WT-FLAG
OST-DA-FLAG
IB: P-InsR
(Y1150/Y1151)
IB: P-InsR
(Y1146)
IB: InsRIB: InsR
IB: FLAG
IB: FLAG
IB: EphB2
IB: EphB2
15 min + EGF 15 min + Ins
Bone
IP: InsR
In vitro dephosphorylation
IP
: F
LA
G
To
ta
l c
el
l l
ys
at
e 
(2
%
)
IB: P-InsR
(Y1150/Y1151) IB: P-InsR(Y1150/Y1151)
IB: P-InsR
(Y1146)
IB: InsR
IB: InsR
IB: P-InsR
(Y1150/Y1151)
IB: InsR
IB: P-EGFR
(Y1068)
IB: EGFR
IP: InsR
In vitro dephosphorylation
GST-OSTPTP WT GST-PTP1B WT
Time (min.)20
Esp-/-WT
105 6030 20 105 6030
Min. 
+ Ins 1u/kg50 3015 12060
GST-OSTPTP DA
-/+ NaVanadate (mM)
0.10 2.50.5 12.5
IB: P-FoxO1
(S256)
IB: FoxO1
GS
T
GS
T-
PT
P1
B 
W
T
GS
T-
PT
P1
B 
DA
GS
T-
OS
TP
TP
 W
T
GS
T-
OS
TP
TP
 D
A
GS
T-
OS
TP
TP
 W
T
GS
T-
OS
TP
TP
 D
A
100
75
C D
Osteoblasts
Coomassie 
staining
W
AT
kDa
100
75
100
75
50
50
37
InsR
Li
ve
r
Mu
sc
le
Ca
lva
ria
OS
B
β−Actin
Fe
m
ur
-- + -- +
+- - +- -
-+ - -+ -
Figure 1. Insulin Receptor Is a Substrate of OST-PTP in Osteoblasts
(A) Western blot analysis of insulin receptor (InsR) expression in tissues and primary osteoblasts (OSB).
(B) In vivo phosphorylation of InsR and EGFR in bone following injection of a bolus of insulin.
(C) In vitro substrate trapping. Extracts from pervanadate-treated ROS17/2.8 cells or primary osteoblasts (OSB) were pulled down using GST or WT and DA
mutants of OST-PTP and PTP1B GST-fusion proteins. InsR was detected by western blot.
(D) In vitro substrate trapping conducted as described in (C) in absence or presence of increasing concentration of sodium orthovanadate (NaVanadate).
(E) In vivo substrate trapping. OST-PTP-WT and –DA FLAG tagged proteins were immunoprecipitated from ROS17/2.8 cells after 15 min stimulation with EGF
(100 ng/ml) or insulin (100 nM). Immunoprecipitated proteins (IP) and total cell lysates were then analyzed by western blot.
(F) In vitro dephosphorylation assay. Hyperphosphorylated InsR was immunoprecipitated (IP) from pervanadate-treated ROS17/2.8 extracts, incubated with
indicated recombinant proteins for 30 min and visualized by western blot.
(G) Time course of InsR dephosphorylation in vitro by OST-PTP and PTP1B. The experiment was conducted as in (F), except incubations were stopped at the
indicated times.
(H) Phosphorylation of InsR and FoxO1 in unstimulated WT and Esp/ osteoblasts.
See also Figure S1.lacking the insulin receptor in only one cell type (Bluher et al.,
2002; Bruning et al., 1998; Konner et al., 2007; Kulkarni et al.,
1999; Michael et al., 2000). Surprisingly, these studies failed to
demonstrate a major influence of insulin signaling in the control
of whole-body glucose homeostasis in two classical insulin
target tissues, muscle, and white fat (Bluher et al., 2002; Bruning
et al., 1998). An implication of these observations is that insulin
may act in additional organs in order tomaintain glucose homeo-
stasis. This hypothesis is consistent with the fact that the insulin
receptor is expressed inmany cell types where its functions have
not yet been analyzed. This is particularly relevant to the osteo-
blast since it expresses the insulin receptor and regulates insulin
secretion (Figure 1A) (Lee et al., 2007).
Here, we show that the insulin receptor is a substrate of
OST-PTP and PTP1B in mouse and human osteoblasts, respec-
tively. As a result, insulin signaling in osteoblasts enhances
osteocalcin activity and impacts glucose homeostasis by
promoting the ability of osteoblasts to enhance bone resorption.
Indeed, because the acid pH in the resorption lacuna allows
protein decarboxylation it is ultimately the activity of the osteo-clast that determines the carboxylation status and function of
osteocalcin secreted by the osteoblast. These results reveal
a pH-dependent mechanism of activation for a hormone and
identify insulin signaling in osteoblasts as a critical link between
bone remodeling and energy metabolism.
RESULTS
The Insulin Receptor Is a Substrate of OST-PTP
in Mouse Osteoblasts
In order to define the mechanism whereby Esp affects osteocal-
cin carboxylation, we asked whether osteocalcin and/or
enzymes required for its carboxylation, g-carboxylase and
Vkorc1 (Sadler, 2004), are phosphorylated on tyrosine residues
and could be substrates of OST-PTP. We failed to detect tyro-
sine phosphorylation of these enzymes or of an osteocalcin
peptide including all tyrosine residues of this molecule (Figures
S1A–S1C available online). We also failed to detect physical
interactions between osteocalcin, g-carboxylase, or Vkorc1,
and OST-PTP (Figures S1D–S1F). Although these negativeCell 142, 296–308, July 23, 2010 ª2010 Elsevier Inc. 297
results must be interpreted cautiously, they imply that OST-PTP
does not affect osteocalcin carboxylation by acting directly on
osteocalcin, g-carboxylase, or Vkorc1.
To pursue our search, we used substrate trapping, an assay
using phosphatase domains in which a single amino acid substi-
tution abrogates their catalytic activity, not their ability to recog-
nize substrates (Flint et al., 1997).
We used OST-PTP active phosphatase domain (Chengalvala
et al., 2001) to test whether the insulin receptor (InsR) was
a substrate of OST-PTP for the following reasons. First, dephos-
phorylation of the InsR by another tyrosine phosphatase, PTP1B,
regulates insulin signaling in other cell types (Delibegovic et al.,
2007; Delibegovic et al., 2009). Second, OST-PTP has homology
in its catalytic domain to phosphatases dephosphorylating the
InsR (Figure S1G). Third, the InsR is abundant in osteoblasts
and treatment of osteoblasts with insulin increases phosphoryla-
tion of the InsR and its downstream targets AKT, GSK3b, FoxO1
and p70S6K (Figure 1A and Figure S1H). Fourth, InsR phosphor-
ylation increased in bone in a time-dependent manner following
insulin injection in vivo (Figure 1B). Furthermore, we reasoned
that if osteoblasts favor glucose homeostasis insulin signaling
should influence osteoblast biology.
The InsR interacted with a mutated form of OST-PTP or of
PTP1B, a positive control, but not with negative controls such
as wild-type (WT) OST-PTP, PTP1B or glutathione S-transferase
(GST); InsR interaction with OST-PTP was competed by
increasing concentrations of orthovanadate, OST-PTP inter-
acted with InsR in cells following insulin treatment only, and
did not interact with an unrelated tyrosine kinase receptor
(Figures 1C–1E). Furthermore, WT OST-PTP dephosphorylated
in vitro InsR while a mutant form of OST-PTP lacking its phos-
phatase activity did not (Figures 1F and 1G). Consistent with
these results, phosphorylation of InsR on tyrosines 1150 and
1151 and of FoxO1, a target of insulin signaling (Puigserver
et al., 2003), was increased in Esp/ osteoblasts (Figure 1H
and Figures S1I and S1J). These experiments provide congruent
biochemical evidence indicating that InsR is a substrate of OST-
PTP in mouse osteoblasts.
Insulin Signaling in Osteoblasts Is a Determinant
of Whole-Body Glucose Metabolism
That insulin signaling in osteoblasts is regulated by OST-PTP,
a phosphatase affecting glucose metabolism, implies that it
also influences this process. To address this question, we gener-
ated osteoblast-specific Insulin Receptor (InsR)-deficient mice
(InsRosb
/ mice) by crossing a1(I)collagen-Cre transgenic
mice, which delete genes in osteoblasts only (Dacquin et al.,
2002), with mice harboring a floxed allele of InsR (Figures S2A–
S2C). Western blot analysis of osteoblasts showed at least
60%deletion of the InsR in osteoblasts but not in liver, pancreas,
white adipose tissue, muscle, and brain of InsRosb
/ mice
(Figures S2D–S2F).
InsRosb
/ mice were born at the expected Mendelian ratio
and at 8 weeks of age presented a significant elevation of blood
glucose in the fed state and a significant reduction of serum
insulin levels in the fasted or fed state, glucagon levels being
unaffected (Figures 2A and 2B and Figure S2G). A glucose-stim-
ulated insulin secretion (GSIS) test verified that insulin secretion298 Cell 142, 296–308, July 23, 2010 ª2010 Elsevier Inc.was decreased in InsRosb
/ mice (Figure 2C). There was also
a decrease in the number of islets, islet size, b-cell mass, b-cell
proliferation and insulin content in InsRosb
/ compared to
control pancreata (Figure 2D). As a result of this decrease in
insulin secretion a glucose tolerance test (GTT) demonstrated
glucose intolerance in InsRosb
/ mice (Figure 2E and
Figure S2H). Insulin tolerance, as measured by an insulin toler-
ance test (ITT), was also significantly reduced in InsRosb
/
compared to control mice (Figure 2F and Figure S2I). Hence,
analysis of InsRosb
/ mice revealed that insulin signaling in
osteoblasts contributes to whole-body glucose homeostasis
by increasing b-cell proliferation and insulin secretion and energy
expenditure (Figure 2H and Figures S2J and S2K).
Insulin often transmits its signal by inhibiting FoxO1 activity.
Since FoxO1 affects glucose homeostasis through its expres-
sion in osteoblasts (Rached et al., 2010a), we asked whether it
was downstream of the insulin signaling pathway in these cells
by generating InsRosb
/ mice lacking one copy of FoxO1 only
in osteoblasts (InsRosb
/;FoxO1osb
+/ mice). As would be
expected if FoxO1 does lie downstream of insulin signaling in
osteoblasts, decreasing its expression corrected the glucose
intolerance of InsRosb
/ mice. This result indicates that inhibit-
ing FoxO1 is a means whereby insulin signaling in osteoblasts
affects glucose homeostasis (Figures 2I–2L).
Insulin Signaling in Osteoblasts Acts Upstream
of Osteocalcin
Since OST-PTP inhibits osteocalcin activity, the observation that
InsR is its substrate implies that insulin signaling in osteoblasts
and osteocalcin lie in the same metabolic pathway.
To test this hypothesis, we first generated mice lacking one
allele of Osteocalcin and one allele of InsR in osteoblasts
(Ocn+/;InsRosb
+/ mice), hypothesizing that if the two genes
lie in the same pathway these compound heterozygous mutant
mice should display a phenotype reminiscent of the one
observed in Ocn/ mice. Indeed, whether we studied glucose
in fed state, insulin secretion, glucose or insulin tolerance,
Ocn+/;InsRosb
+/ mice had metabolic abnormalities similar to
the ones of Ocn/ mice (Figures 3A–3E), InsRosb
+/ and
Ocn+/ mice were undistinguishable from control littermates.
Likewise, if OST-PTP inhibits the function of insulin signaling
in osteoblasts one would anticipate that the metabolic pheno-
type of Esp/ mice should be corrected by decreasing insulin
signaling in osteoblasts. Accordingly, removing one allele of
InsR in osteoblasts from Esp/ mice normalized glucose
and insulin tolerance (Figures 3F–3H). These two experiments
provide genetic evidence that a function of insulin signaling
in osteoblasts is to favor osteocalcin metabolic activity
(Figure 3I).
That reducing insulin signaling in osteoblasts corrected the
enhanced glucose and insulin tolerance of Esp/ mice was
important in its own right, because it indicated that themetabolic
phenotype of Esp/ mice is secondary to an increase in insulin
signaling in osteoblasts. This contention is supported by the
increased phosphorylation of the InsR in Esp/ osteoblasts
(Figure 1H). Thus, in subsequent experiments studying insulin
signaling in osteoblasts, we relied on both loss- (InsRosb
/)
and gain-of-function (Esp/) models.
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Figure 2. Decreased Insulin Secretion, Glucose Tolerance, and Insulin Tolerance in InsRosb
/ Mice
All experiments compare 8- to 12-week-old male mice. Genotypes are indicated in each panel.
(A) Random-fed blood glucose levels.
(B) Fasted and random-fed insulin levels.
(C) GSIS.
(D) Pancreas insulin content and histomorphometric comparisons of islet number, islet size, b-cell mass, and Ki67 immunoreactive cells in pancreatic islets.
(E) GTT.
(F) ITT.
(G) Area under the curve of (C), (E), and (F).
(H) Energy-balance data: oxygen consumed (VO2), carbon dioxide produced (VCO2), and heat.
(I–K) Rescue of the InsRosb
/ phenotype by FoxO1 haploinsufficiency, (I) GSIS, (J) GTT, (K) ITT.
(L) Area under the curve of (I)–(K).
*p < 0.05, **p < 0.01, and ***p < 0.001 versus InsRfl/fl in (A)–(H) (t test or ANOVA) or versus InsRfl/fl and InsRosb
/;FoxO1osb
+/ in (I)–(L) (ANOVA).
See also Figure S2.Insulin Signaling in Osteoblasts Inhibits Osteocalcin
Carboxylation
To ascertain that insulin signaling in osteoblasts regulates
osteocalcin activity, we developed a dual ELISA quantifying
the ratio between undercarboxylated, i.e., active (GLU), and
carboxylated, i.e., inactive (GLA), circulating osteocalcin
(Figures S3A–S3E).
This ELISA detected an increase in undercarboxylated osteo-
calcin inEsp/mice,whichharbor an increase in insulin signaling
in osteoblasts (Figure 1H) but not in Esp/;InsRosb
+/ mice that
do not (Figure 3J). In contrast, it showed that undercarboxylated
osteocalcin levels were decreased when insulin signaling is
impaired in osteoblasts (InsRosb
/ mice), even though Ocnexpression and serum levels were not affected (Figure 3J and
Figures S3F and S3G). A decrease in undercarboxylated osteo-
calcin was also observed in Ocn+/;InsRosb
+/ mice that display
a glucose intolerance similar to the one of the Ocn/ and
InsRosb
/mice (Figure3JandFigureS3H).Thesemeasurements
of undecarboxylated osteocalcin in variousmutantmouse strains
along with the genetic evidence presented above indicate that
insulin signaling in osteoblasts inhibits osteocalcin carboxylation,
i.e., is a positive regulator of its metabolic activity.
Insulin Signaling in Osteoblasts Favors Bone Resorption
In a separate line of work, we noticed a marked decrease in the
serum level of CTx, a marker of bone resorption, in InsRosb
/Cell 142, 296–308, July 23, 2010 ª2010 Elsevier Inc. 299
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All experiments compare 6- to 8-week-old male mice unless otherwise noted.
(A) Random-fed blood glucose level.
(B) GSIS.
(C and F) GTT.
(D and G) ITT.
(E) Area under the curve of (B)–(D).
(H) Area under the curve of (F) and (G).
(I) Model of insulin signaling in osteoblasts.
(J) Carboxylation levels of serum osteocalcin assessed by GLU/GLA dual ELISA.
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*p < 0.05 versus InsRfl/fl (t test). p < 0.05 versus InsRfl/+ (t test).
See also Figure S3.mice, whereas this parameter was increased in Esp/ mice
(Figure 4A). This data suggested that insulin signaling in osteo-
blasts favors bone resorption. Although not the focus of this study,
bone formationparameterswereseverelydecreased in InsRosb
/
mice; as a result, these mice had a low bone mass (Figure S4A).300 Cell 142, 296–308, July 23, 2010 ª2010 Elsevier Inc.To prove that insulin signaling in osteoblasts affects bone
resorption, we used a coculture assay of osteoblasts and
osteoclasts (Takahashi et al., 1988). When cocultured with WT
osteoblasts, WT osteoclast precursor cells differentiated and
formed resorption pits. When WT osteoclast precursor cells
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Figure 4. Insulin Signaling in Osteoblasts
Favors Osteoclast Function
Mice genotypes are indicated in each panel.
(A) CTx serum levels in 8-week-old mice.
(B) Differentiation and resorptive ability of osteo-
clasts cocultured in presence of control or mutant
osteoblasts.
(C) Expression of Opg, Rankl, and Csf1 in mouse
osteoblasts by real-time PCR.
(D) Secretion of OPG by Esp/ and WT osteo-
blasts.
(E) Opg expression and OPG secretion by osteo-
blasts following a 4 hr and 24 hr insulin treatment,
respectively.
(F) Dose-dependent effects of OPG on differentia-
tion and resorptive ability of osteoclasts in pres-
ence of 30 ng/ml RANKL and 10 ng/ml M-CSF.
Representative pictures of TRAP staining and pit
assay (left panel). Quantification of the number of
the pits area (middle panel) and of TRAP positive
cells (right panel).
(G and H) Real-time PCR analysis of Opg expres-
sion and/or secretion in ROS17/2.8 osteoblastic
cells transfected with empty (pFLAG) or FoxO1
expression (FoxO1-FLAG) vector (G) or in mouse
osteoblasts transfected with control siRNA (Con
siRNA) or FoxO1 siRNA (H).
(I and J) Expression of Opg in bone (I) and CTx
serum levels (J) in 1- and 3-month-old mice.
(K and L) Real-time PCR analysis of Ctsk, Tcirg1
and Trap expression in bone (K) and in osteoclasts
cocultured in presence of control or InsR/ oste-
oblasts (L).
(M) Real-time PCR analysis of the Opg/Rankl
expression ratio in bones of 3-month-old male
mice.
In (A)–(D), (G)–(I), (K), and (L), *p< 0.05 and **p< 0.01
versus corresponding controls (t test). In (F), *p <
0.05 versus 0 ng/ml OPG (t test). In (E), *p < 0.05,
**p < 0.01, and ***p < 0.001 versus WT+vehicle
(ANOVA). In (J) and (M), *p < 0.05 versus InsRfl/fl
and InsRosb/;FoxO1osb+/ (ANOVA).
See also Figure S4.were cocultured with InsR/ osteoblasts, the area covered by
resorption pits was significantly decreased, whereas it increased
50% when cocultured with Esp/ osteoblasts (Figure 4B). That
the number of osteoclasts was unaffected whether we used
Esp/ or InsR/ osteoblasts (Figure 4B) is consistent with the
notion that insulin signaling in osteoblasts promotes only the
function of osteoclasts.
We next studied expression of genes influencing bone
resorption in osteoblasts and noticed that expression of
Osteoprotegerin (Opg), a gene encoding a decoy receptor for
RANKL and a negative regulator of osteoclast function (Teitel-
baum and Ross, 2003), was increased 2-fold in InsR/ andCell 142, 296–decreased 50% in Esp/ osteoblasts;
its secretion followed the same pattern
(Figures 4C–4E). That insulin treatment
of WT but not of InsR/ osteoblasts
decreasedOpg expression and secretion
verified that it is an insulin target gene inosteoblasts (Figure 4E). To demonstrate that a moderate
increase in OPG secretion inhibits the activity rather than the
differentiation of osteoclasts, we cultured osteoclast progenitor
cells in the presence of increasing amount of OPG (0–90 ng/ml).
Low amounts of OPG in the culture medium decreased the
surface covered by resorption pits but not the osteoclasts
number (Figure 4F).
Multiple evidences indicated that insulin signaling in osteo-
blasts favors bone resorption by inhibiting FoxO1. First, Opg
expression was increased 2-fold in ROS17/2.8 osteoblastic cells
overexpressing FoxO1 (Figure 4G). Second, siRNA-mediated
downregulation of FoxO1 decreased Opg expression and308, July 23, 2010 ª2010 Elsevier Inc. 301
secretion in mouse osteoblasts (Figure 4H and Figure S4B).
Third, the increase in bone resorption noted in FoxO1obs
/
mice (Rached et al., 2010b) could be traced to a decrease in
Opg expression in bone (Figure 4I). Fourth, removing one allele
of FoxO1, in osteoblasts only, from InsRosb
/ mice normalized
bone resorption (Figure 4J).
Insulin Signaling in Osteoblasts Promotes the
Osteoclasts Ability to Acidify the Bone Extracellular
Matrix
Next, we sought to identify Opg-dependent molecular events
taking place in osteoclasts under the control of insulin signaling
in osteoblasts. Expression of CathepsinK (Ctsk) and Tcirg1,
two genes implicated in bone resorption, was decreased in
InsRosb
/ and increased in Esp/ bones (Figure 4K). Ctsk
and Tcirg1 expression was also decreased in osteoclasts ob-
tained following coculture of WT osteoclast precursors cells
with InsR/ osteoblasts (Figure 4L). For the rest of this study
we focused on Tcirg1, a gene encoding a vacuolar proton
pump subunit essential for acidification of the bone extracellular
matrix (ECM), precisely because acidification of the bone ECM is
a prerequisite for bone resorption (Teitelbaum and Ross, 2003).
Taken together, the biochemical, molecular, and genetic
evidence presented above indicates that insulin signaling in
osteoblasts decreases Opg expression and the Opg/Rankl ratio
(Figure 4M); this results in an increase in Tcirg1 expression, in
ECM acidification, and in bone resorption.
Bone Resorption as a Means to Decarboxylate
Osteocalcin
An acid pH can decarboxylate proteins (Engelke et al., 1991),
and this raises the prospect that bone resorption, which occurs
at an acid pH, can decarboxylate osteocalcin in vivo.
To verify that an acid pH could decarboxylate and activate
osteocalcin, equal amounts of carboxylated osteocalcin were
incubated for 2 weeks at 37C in solutions buffered at either
pH 7.5 or pH 4.5, the latter being the pH present in the resorption
lacunae (Silver et al., 1988). Each osteocalcin solution was then
analyzed by high-resolution mass spectrometry. This revealed
a peak at m/z 1325.103(+4) corresponding to a form of osteocal-
cin in which all three glutamic residues are carboxylated (molec-
ular weight: 5296.42 Da) and another peak at m/z 1314.108 (+4)
corresponding to an osteocalcin form in which one of the three
glutamic residues was not carboxylated (molecular weight:
5252.43 Da) (Figure 5A). The mass difference between these
two forms is 43.9 Da, which corresponds to one carboxylation
modification.
Importantly, the ratio of undercarboxylated to fully carboxyl-
ated osteocalcin was significantly increased when osteocalcin
was incubated at pH 4.5 (Figure 5A and Figure S5A). Tandem
mass spectrometry analysis of trypsin-digested samples
demonstrated that the presence of a GLU residue at position
13 was increased more than 2-fold upon incubation at pH 4.5
(Figure 5B), thus suggesting that this residue is highly suscep-
tible to decarboxylation. We also assessed themetabolic activity
of these two preparations of osteocalcin. When rat insulinoma
INS-1 cells were treated with carboxylated (pH 7.5) or undercar-
boxylated (pH 4.5) osteocalcin, only the latter form could302 Cell 142, 296–308, July 23, 2010 ª2010 Elsevier Inc.increase insulin secretion to the same extent as recombinant un-
carboxylated osteocalcin used as a positive control (Ferron et al.,
2008) (Figure 5C).
Given these results, we cultured osteoclast precursor cells in
the presence or absence of RANKL on bovine cortical bone
slides devitalized to exclude any endogenous osteoblastic
activity. Two days after osteoclasts were identifiable, total, car-
boxylated, and undercarboxylated osteocalcin were measured.
When osteoclast differentiation had been triggered by RANKL,
the levels of total and undercarboxylated (GLU) osteocalcin
were increased, while that of carboxylated (GLA) osteocalcin
was decreased. As a result, there was a 2-fold increase in the
GLU/GLA ratio (Figures 5D and 5E). Thus, the resorptive activity
of osteoclasts suffices to activate osteocalcin.The Osteoclast Ability to Acidify the Bone ECM Favors
Glucose Homeostasis
Given the role of osteocalcin in glucose metabolism, we next
asked whether the osteoclasts ability to activate osteocalcin
affects glucose metabolism. For that purpose we analyzed
oc/oc mice harboring a loss-of-function mutation in Tcirg1 re-
sulting in osteopetrosis (Scimeca et al., 2000). The level of under-
carboxylated osteocalcin was decreased 30% in oc/oc
compared to WT serum (Figure 5F). Accordingly, conditioned
mediumof oc/oc calvaria cultures did not stimulate insulin secre-
tion by INS-1 cells (Figure 5G). Hence, in oc/ocmicewhose oste-
oclasts cannot acidify the bone ECM, circulating osteocalcin is
metabolically inactive.
Importantly, for our purpose, oc/oc mice were also glucose
intolerant (Figures 5H and 5I) with a marked decrease in serum
insulin levels, pancreas insulin content, and Insulin expression
in pancreas (Figures 5J–5L). To determine whether this pheno-
type was secondary to a function of Tcirg1 in osteoclasts, we
transplanted oc/oc fetal liver hematopoietic stem cells into WT
irradiated mice. Transplantation of mutant hematopoietic stem
cells resulted in high bonemass inWT recipient animals because
their osteoclasts could not form resorption pits (Figure 5M and
Figures S5B–S5F). Fasting glucose blood levels were increased
while serum insulin levels in fasted and fed states were
decreased in mice transplanted with oc/oc cells (Figures 5N
and 5O). A GSIS test demonstrated a defect in insulin secretion
in these mice, whereas a GTT showed glucose intolerance
(Figures 5P–5R). Energy expenditure was also decreased in
WT mice transplanted with oc/oc cells (Figure 5S and Figures
S5G and S5H). As expected, in mice transplanted with oc/oc
cells, there was a significant decrease in serum undercarboxy-
lated osteocalcin while the total osteocalcin level was
unchanged (Figure 5T and Figure S5I). These results demon-
strate that the osteoclasts ability to acidify the bone ECM is
both necessary and sufficient to activate osteocalcin and to
influence whole-body glucose metabolism.Insulin Signaling in Osteoblasts Favors Glucose
Homeostasis in a Bone Resorption-Dependent Manner
The observations presented above beg the following question: Is
it because it favors bone resorption that insulin signaling in oste-
oblasts promotes glucose homeostasis?
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Figure 5. An Acidic Environment Suffices to Decarboxylate Osteocalcin g-Carboxyglutamic Acid 13
(A) High-resolution mass spectrometry analysis of carboxylated osteocalcin incubated for 2 weeks at pH 7.5 or pH 4.5.
(B) Tandem mass spectrometry analysis of trypsin-digested samples of carboxylated osteocalcin incubated at pH 7.5 and pH 4.5.
(C) Insulin secretion from INS-1 cells following a 1 hr treatment with the indicated forms of osteocalcin.
(D) Total, GLA, and GLU osteocalcin released from bovine bone slices seeded with osteoclast progenitors treated with RANKL or vehicle or medium alone
measured by ELISA.
(E) GLU/GLA ratio of the osteocalcin released from bovine bone slices seeded with osteoclast progenitors treated with RANKL or vehicle and osteocalcin
chemically extracted from bone slide measured by dual ELISA.
(F–L) Analysis of 2- to 3-week-oldWT and oc/ocmice. (F) Carboxylation ratio of serum osteocalcin measured by dual ELISA. (G) Insulin secretion from INS-1 cells
following a 1 hr treatment with conditioned media (CM) from ex vivo cultures of calvaria from WT and oc/ocmice. (H) GTT at 2 weeks of age by IP injecting mice
wth glucose (1 g/kg) under random-fed condition. (I) Area under the curve of (H). (J) Random-fed insulin levels. (K) Pancreas insulin content. (L) Expression of
Insulin genes (Ins1 and Ins2) and Glucagon (Gcg) in pancreas by real-time PCR.
(M–T) Analysis of 10- to 12-week-oldWTmice transplanted with either WT (WT +WT) or oc/oc (WT + oc/oc) fetal liver hematopoietic stem cells. (M) Quantification
of the resorptive ability of osteoclasts derived from transplantedmice cultured in presence of RANKL andM-CSF. (N) Fasted blood glucose levels. (O) Fasted and
random-fed insulin levels. (P) GSIS. (Q) GTT. (R) Area under the curve of (P) and (Q). (S) Energy-balance data: oxygen consumed (VO2), carbon dioxide produced
(VCO2), and heat. (T) Carboxylation ratio of serum osteocalcin measured by dual ELISA.
In (C), **p < 0.01 and ***p < 0.001 versus control andGLA-OCNpH7.5 (ANOVA). In (D), (E), and (G), *p < 0.05 and **p < 0.01 versus control and/ormedium (ANOVA).
In (F), (I–O), and (R–T), *p < 0.05 and **p < 0.01 versus WT (t test). In (H), (P), and (Q), *p < 0.05 and **p < 0.01 versus WT (ANOVA).
See also Figure S5.
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To determine whether the influence of insulin signaling in oste-
oblasts on glucose metabolism depends on the osteoclasts
ability to acidify the bone ECM, we generated mice lacking
one allele of InsR in osteoblasts and harboring one oc allele
(InsRosb
+/;oc/+mice). In these mutant mice, osteocalcin under-
carboxylation was markedly decreased (Figure 6A); as a result
of this shift toward decreased osteocalcin activity, insulin secre-
tion, glucose, and insulin tolerance were impaired in InsRosb
+/
;oc/+ but not in InsRosb
+/ or oc/+ mice (Figures 6B–6D and
Figure S6A). These data genetically link insulin signaling in oste-
oblasts, bone resorption, and whole-body glucose homeostasis.
If insulin signaling in osteoblasts promotes glucose homeo-
stasis in a bone resorption-dependent manner, then inhibiting
bone resorption in a model of increased insulin signaling in oste-
oblasts, such as the Esp/mice, should correct their metabolic
phenotypes. Indeed, and unlike Esp/ mice, Esp/;oc/+ mice
had normal bone resorption, normal osteocalcin carboxylation
status (Figures 6E and 6F), normal insulin secretion, normal
glucose, and insulin tolerance (Figures 6G–6I and Figure S6B).
Likewise, when we treated Esp/ mice with alendronate, an
inhibitor of osteoclast activity (Fisher et al., 1999), osteocalcin
carboxylation, insulin secretion, glucose, and insulin tolerance
were normalized (Figures 6J–6N and Figure S6C).
Lastly, if insulin signaling in osteoblasts promotes glucose
metabolism by increasing bone resorption, stimulating bone
resorption should rescue, at least partially, glucose intolerance
in WT mice. To test this contention, we fed WT mice a high-fat
diet and treated them with RANKL or GST as a negative control.
As expected, RANKL increased bone resorption parameters
(Figures S6D and S6E). This increase in bone resorption led to
a 3-fold increase in serum levels of undercarboxylated osteocal-
cin (Figure 6O). RANKL-treated mice fed a high-fat diet secreted
more insulin, were significantly less glucose intolerant, more
insulin tolerant and less fat than GST-treated mice (Figures 6P–
6S and Figure S6F). These three experiments demonstrate that
insulin signaling in osteoblasts cannot affect osteocalcin activity
and glucose metabolism if bone resorption is impaired.
Insulin Signaling in Human Osteoblasts, Bone
Resorption, Osteocalcin Activity, and Glucose
Homeostasis
Clinical studies indicate that osteocalcin is involved in glucose
homeostasis in humans (Hwang et al., 2009; Kanazawa et al.,
2009; Pittas et al., 2009). However, since ESP is a pseudogene
in humans (Cousin et al., 2004) osteocalcin activity must be regu-
lated by another phosphatase. The identification of InsR as a
substrate of OST-PTP provided a way to address this question.
We asked whether PTP1B, a tyrosine phosphatase able to
dephosphorylate INSR, was present in human osteoblasts.
PTP1B was markedly more abundant in human than in mouse
osteoblasts and decreasing its expression in human osteoblasts
increased INSR and FOXO1 phosphorylation and decreased
OPG expression (Figures 7A–7D). Conversely, siRNA-mediated
knockdown of INSR in human osteoblasts decreased FOXO1
phosphorylation and increased OPG expression (Figures 7D
and 7E). Finally, PTP1B could trap INSR in human osteoblasts
(Figure 7F). Thus, insulin signaling in human osteoblasts is regu-
lated by a tyrosine phosphatase and favors bone resorption.304 Cell 142, 296–308, July 23, 2010 ª2010 Elsevier Inc.The observations made in mice imply that patients harboring
a defect in bone resorption (osteopetrosis) should have low
serum undercarboxylated osteocalcin and serum insulin levels.
We tested this contention by analyzing patients with an auto-
somal dominant form of osteopetrosis. Three patients had
amissensemutation inClCN7, a gene required for acid secretion
in the resorption lacuna (Schaller et al., 2005); for the others,
although no genetic defect could be identified, a decrease of
acidification ability was demonstrated in osteoclasts cultured
ex vivo in presence of LysoSensor fluorescent pH indicators
(Figures S7A and S7B). Circulating undercarboxylated osteocal-
cin was significantly decreased in all patients, as were serum
insulin levels measured after feeding (Figure 7G). These data
support the notion that osteocalcin activity is determined in
humans, in part, by bone resorption, an aspect of bone remodel-
ing regulated by insulin signaling in osteoblasts.
DISCUSSION
This study demonstrates that insulin signaling in osteoblasts is
a significant determinant of whole-body glucose homeostasis.
Taking full advantage of the interplay between osteoblasts and
osteoclasts characterizing bone remodeling, insulin signaling in
osteoblasts achieves this function by favoring osteocalcin
decarboxylation (Figure 7H). Thus, this study identifies insulin
as a key molecular link between bone remodeling and energy
metabolism.
Insulin Signaling in Osteoblasts and Glucose
Homeostasis
Insulin signaling and functions in various tissues have been
extensively studied in vivo in the last 10 years using mutant
mouse strains lacking the insulin receptor in only one cell type.
These studies have redefined the respective contributions of
various cell types to whole-body glucose homeostasis. For
instance, they showed that insulin signaling in b-cells is needed
for insulin secretion and, as expected, insulin signaling in
hepatocytes is needed for insulin sensitivity (Kulkarni et al.,
1999; Michael et al., 2000). In contrast, deletion of this receptor
in white adipose tissue (WAT) resulted in an improvement of
glucose metabolism (Bluher et al., 2002). Taken together these
various studies imply that insulin exerts yet to be identified
functions in other tissues, an idea congruous with the fact that
the insulin receptor is expressed in many cell types where its
function has not been studied yet.
In agreement with this hypothesis, we show here, through
the analysis of both loss- and gain-of-function models, that
insulin signaling in osteoblasts influences whole-body glucose
homeostasis by promoting insulin secretion. To the best of our
knowledge osteoblasts and hepatocytes are the only cell types
in which disrupting insulin signaling hampers glucose metabo-
lism in mice fed a normal diet.
Insulin Signaling in Osteoblasts, Osteocalcin Activation,
and Bone Resorption
One issue surrounding osteocalcin biology has been elucidating
how the intracellular phosphatase OST-PTP could favor carbox-
ylation. Here, we identify the insulin receptor as a bona fide
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Figure 6. Insulin Signaling in Osteoblasts Favors Glucose Homeostasis by Promoting Bone Resorption
(A–I) Analysis of 7- to 9-week-old (A–D) or 6- to 7-week-old (E–I) male mice of indicated genotypes.
(J–N) Analysis of 6-week-old WT and Esp/ mice treated with vehicle (Veh.) or alendronate (Alend., 80 mg/kg/week) for 4 weeks.
(O–S) Analysis of 16-week-old WT mice fed a normal or a high-fat diet (HFD) and treated with GST or GST-RANKL (0.8 mg/kg/day) for 8 weeks.
(A, F, K, and O) Carboxylation ratios of serum osteocalcin measured by dual ELISA.
(B, G, L, and P) GSIS.
(C, H, M, and Q) GTT.
(D, I, N, and R) ITT.
(E and J) CTx serum levels.
(S) Epididymal fat pad mass.
In (A), p < 0.05 versus InsRfl/+ and InsRosb+/ (ANOVA). In (B)–(D), *p < 0.05 versus InsRfl/+, InsRosb+/, and InsRfl/+;oc/+ (ANOVA). In (E)–(I), *p < 0.05
versus WT, Esp/;oc/+, and oc/+ (ANOVA). In (J)–(N), *p < 0.05 and **p < 0.01 versus WT and Esp/ +Alend (ANOVA). In (O) and (S), *p < 0.05 and **p <
0.01 versus GST group (t test). In (P)–(R), *p < 0.05 and **p < 0.01, and ***p < 0.001 versus normal diet and GST groups (ANOVA).
See also Figure S6.
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Figure 7. Insulin Signaling in Human Osteoblasts and Glucose Homeostasis
(A) Western blot analysis of PTP1B expression in human and mouse osteoblasts (OSB).
(B) Phosphorylation of INSR in human osteoblasts transfected with control (Con) or PTP1B siRNA.
(C) Phosphorylation of FOXO1 in human osteoblasts transfected with control (Con) or PTP1B siRNA.
(D) Real-time PCR analysis of OPG and CSF1 expression in human osteoblasts transfected with control siRNA (Con siRNA) or INSR siRNA or PTP1B siRNA.
(E) Phosphorylation of FOXO1 in human osteoblasts transfected with control (Con) or INSR siRNA.
(F) In vivo trapping of INSR by PTP1B DA mutant in human osteoblasts.
(G) Insulin levels (90 min postfeeding) and osteocalcin carboxylation ratio assessed by dual ELISA in human patients affected with dominant osteopetrosis (ADO)
and normal controls.
(H) Model of the bone resorption-dependent activation of osteocalcin by InsR. Insulin signaling in osteoblasts, which is inhibited by Esp, decreases in a
FoxO1-dependent manner OPG expression. This promotes bone resorption and in particular Tcigr1 expression and acidification of the bone ECM, which
promotes osteocalcin decarboxylation and as a result b-cells proliferation, insulin secretion, and insulin sensitivity.
See also Figure S7.substrate of OST-PTP. This finding means that the metabolic
phenotype of the OST-PTP-deficient mice characterized by
improved whole-body glucose homeostasis (Lee et al., 2007) is
due to an increase in insulin signaling in osteoblasts.
More importantly, since OST-PTP regulates osteocalcin
function these results also placed de facto insulin signaling in
osteoblasts upstream of osteocalcin. To increase osteocalcin
bioactivity insulin signaling in osteoblasts acts in a ricocheting
manner using the huge amount of osteocalcin stored in the
bone ECM and the interplay between osteoblasts and osteo-
clasts. Specifically, it takes advantage of the ability of the
osteoblast to promote bone resorption. Since an acid pH is the
only known chemical condition allowing protein decarboxylation
(Engelke et al., 1991), bone resorption, which occurs at pH 4.5,
provides an ideal setting to decarboxylate and activate osteocal-
cin (Figure 7H).
The positive feedback loop existing between insulin signaling
in osteoblasts and osteocalcin functions implies that negative
regulators of this process may also exist. Leptin, another
hormone exerting a major influence on energy metabolism, is
one of them and does so also by modulating Esp expression
(Hinoi et al., 2008). Thus, these studies highlight the unexpected
importance of Esp in orchestrating the endocrine function of
bone.306 Cell 142, 296–308, July 23, 2010 ª2010 Elsevier Inc.Another issue about osteocalcin biology has been to provide
evidence that it has the same function in humans. Several argu-
ments indicate that it is the case. First, the tyrosine phosphatase
PTP1B fulfills in human osteoblasts the function that OST-PTP
fulfills in mouse osteoblasts. Second, insulin signaling in human
osteoblasts regulates OPG expression as it does in mouse
osteoblasts. Third, osteopetrotic patients and mice display the
same increase in osteocalcin carboxylation and decrease in
insulin blood levels. These results support a growing number of
observations linking osteocalcin or warfarin, a compound
decreasing its carboxylation, to the regulation of glucose
homeostasis in humans (Hwang et al., 2009; Kanazawa et al.,
2009; Pittas et al., 2009; Scheen, 2005). The notion that
hampering bone resorption has deleterious consequences on
glucose homeostasis is medically important since most drugs
used to treat osteoporosis target this aspect of bone remodeling.
Specifically, fasting plasma glucose levels are elevated in
osteoporotic women treated with drugs inhibiting bone resorp-
tion and serum undercarboxylated osteocalcin levels are
positively correlated with bone resorption in healthy women
(Kaji et al., 2009; Yamauchi et al., 2010).
Lastly, this work expands the relationship existing between
bone remodeling and energy metabolism (Karsenty, 2006) and
raises the testable hypothesis that the skeleton may exert
additional endocrine influences on other, yet to be identified,
physiological functions.
EXPERIMENTAL PROCEDURES
Mice Generation
Generation of Esp/ (C57BL/6J;129/Sv), Ocn/ (C57BL/6J;129/Sv), and
FoxO1obs
/ (C57BL/6J;BALB/c) mice was reported (Dacquin et al., 2004;
Ducy et al., 1996; Rached et al., 2010a). InsRobs
/ mice were generated by
intercrossing the progeny of crosses between InsRflox/flox mice, that harbor
LoxP sites within introns 3 and 4 (Figure S2A), and a1(I)collagen-Cre transgenic
mice (Dacquin et al., 2002). oc/+ mice (C57BL/6J;C3H) were obtained
from The Jackson Laboratory. Genetic backgrounds of mice are as follows:
InsRosb-/- (C57BL/6J:87.5%; 129/Sv:12.5%), Ocn
+/;InsRosb
+/ and Esp/
;InsRosb
+/ (C57BL/6J;129/Sv), FoxO1osb
+/;InsRosb
/ (C57BL/6J;BALB/c;
129/Sv), oc/+;InsRosb
+/ (C57BL/6J;C3H;129/Sv). Control littermates were
used in all experiments. Mice genotypes were determined by PCR; primer
sequences are available upon request. CD45.2+ fetal liver stem cells isolated
from E14.5 WT or oc/oc embryos were transplanted (2 3 106/mice) via tail
vein injection into 5-week-old CD45.1+-irradiated WT recipient mice. Hemato-
poietic reconstitution was quantified by FACS analysis of blood cells collected
10 weeks posttransplantation (Figures S6B–S6E).
Metabolic Studies and Bioassays
Glucose tolerance test (GTT), glucose stimulated insulin secretion (GSIS),
insulin tolerance test (ITT), pancreas insulin content, histology, and high-fat
diet studies were performed as described (Lee et al., 2007). ELISA were
used tomeasuremouse/human insulin (Mercodia), plasma glucagon (ALPCO),
mouse CTx (RatLaps, IDS), bovine/human osteocalcin carboxylation ratios
(Takara), human TRAP (Bone TRAP Assay, IDS) and human CTx (Serum
Crosslaps, IDS).
Biochemistry and Gene Expression Studies
A complete description of all biochemical experiments is available as
Extended Experimental Procedures. All antibodies were obtained from Cell
Signaling Technology, with the exception of anti-PTP1B (R&D), anti-FLAG,
and anti-b-actin (Sigma). RNA isolation, cDNA preparation, and real-time
PCR analyses were carried out following standard protocols. Substrate-
trapping was conducted as described (Flint et al., 1997). Briefly, extracts
from pervanadate-treated cells were incubated in the presence of GST
recombinant protein and washed four times with lysis buffer. For in vitro
dephosphorylation assays, ROS17/2.8 cells were treated with pervanadate
(100 mM) for 30 min, and InsR was immunoprecipated. The immune complex
was then incubated at 30C in the presence of 1 mg of recombinant GST,
GST-PTP, or GST-PTPDA for indicated times. Phosphorylation of InsR was
visualized by western blot. In in vivo trapping experiments, MG-63 or
ROS17/2.8 cells were transfected with FLAG-tagged expression vector, and
complexes were immunoprecipitated using anti-FLAG antibodies.
Cell Culture
Human osteoblastic cells hFOB 1.19, Saos-2 (ATCC) or mouse primary oste-
oblasts were transfected with siRNA pools (On-target, Dharmacon) according
to the manufacturer instructions. InsR+/+ and InsR/ osteoblasts were
generated ex vivo by infecting InsRflox/flox with either GFP- or Cre-expressing
adenovirus (University of Iowa). Bone marrow progenitor cells and osteoblasts
cocultures were performed as previously described (Takahashi et al., 1988).
In vitro resorption activity of osteoclasts was measured using BD BioCoat
Osteologic Bone Cell Culture System.
Mass Spectrometry
Synthetic carboxylated osteocalcin (Bio-Synthesis Inc.) was incubated at
37C in pH 7.5 or pH 4.5 0.1 M phosphate buffer for 2 weeks. Mass spectrom-
etry was run using Bruker Apex 9.4T Fourier Transform Ion Cyclotron
Resonance (FT-ICR) Mass Spectrometer and Daltonics DataAnalysis software
(v. 3.4) for analysis. Comparative quantification between carboxylated and
undercarboxylated osteocalcin were made based on exact mass measure-ments and fit of isotopic peaks to that of theoretical isotopic patterns
(SNAP2 algorithm).
Statistics
Results are given as means ± standard errors of the mean except in human
studies in which standard deviations were used. Statistical analyses were
performed using unpaired, two-tailed Student’s t test for comparison between
two groups and One-way ANOVA test for more than two groups comparison.
For GTT, ITT, and GSIS, we performed two-way mixed designed ANOVA
and calculated Area Under the Curve (AUC) followed by student’s t test or
One-way ANOVA. For all experiments (*p or #p) % 0.05, (**p or ##p) % 0.01,
***p% 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
Supplemental References, and seven figures and can be found with this article
online at doi:10.1016/j.cell.2010.06.003.
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